ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveInsight, maintaining an essence of brevity, has compiled the conference’s major highlights so that you do not miss out on these expansions in hematology.

Follicular Lymphoma Highlights: ASH 2021

Major Pharma companies involved in presenting their FL data readouts during the conference included Roche, Novartis, BMS, Incyte,and Genmab.

  • Innovent Biologics announced durable responses of parsaclisib in R/R FL from a Phase II trial: Major Key player Innovent Biologics announced the results from its pivotal Phase II study for parsaclisib in patients with relapsed or refractory (R/R) FL. As per the key results presented at ASH 2021, in the 24 evaluable patients with R/R FL, the ORR was reported to be 91.7%, CR was 6.7 %, and PR was 75%. Parsaclisib was found to be well tolerated with a manageable safety profile. After analyzing the trial results, DelveInsight believes that parsaclisib is a promising drug and may provide valuable treatment for patients with R/R FL.
  • Fixed-duration treatment with mosunetuzumab inducing deep and durable responses in heavily pretreated patients with R/R FL: Roche presented the trailblazing data from their pivotal Phase I/II study in patients with R/R FL who have received ≥2 prior lines of therapy. The company also mentioned that mosunetuzumab is the first T-cell–engaging bispecific antibody to demonstrate clinically meaningful outcomes by meeting the primary endpoint for patients with R/R FL in a pivotal Phase II setting. According to the results presented, DelveInsight believes that mosunetuzumab could potentially become a highly efficacious treatment option that can be administered without cell collection or genetic engineering.
  • Roche also presented early phase data from its Ib study evaluating mosunetuzumab in combination with lenalidomide in patients with R/R FL, which demonstrated encouraging preliminary efficacy and a tolerable safety profile.
  • Novartis announced strong responses of Kymriah (tisagenlecleucel) in a Phase II ELARA study in patients with high-risk R/R FL: According to the positive results presented at ASH 2021, Novartis mentioned that Kymriah induced high rates of durable responses in patients for the majority of high-risk disease subgroups, who typically have a poor prognosis. The company revealed that Kymriah was well tolerated as patients have been experiencing long-lasting responses with a low risk of severe adverse events, which will potentially lead to transformative results and a positive impact on the health system.